NCT04414345View on ClinicalTrials.gov

HEALEY ALS Platform Trial - Regimen C CNM-Au8

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

April 13, 2022

Study Completion Date

March 7, 2023

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

CNM-Au8

"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"

DRUG

Matching Placebo

"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"

Trial Locations (1)

02114

Healey Center for ALS at Mass General, Boston

Sponsors

Collaborators (1)

Clene Nanomedicine
All Listed Sponsors
collaborator

Clene Nanomedicine

INDUSTRY

lead

Merit E. Cudkowicz, MD

OTHER

NCT04414345 - HEALEY ALS Platform Trial - Regimen C CNM-Au8 | Biotech Hunter | Biotech Hunter